ArticleNature biotechnology2021
Alternative hosts as the missing link for equitable therapeutic protein production.
Article in Nature biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Host-Informed Engineering of Glycosylation in Komagataella phaffii for Human Biantennary N-Linked Glycans.Research square · 2026Article
- Deletion of low-essentiality, secretion-associated genes enhances recombinant protein production in Komagataella phaffii.Microbial cell factories · 2026Article
- Efficient Extracellular Production of Insulin Glargine in Trichoderma reesei by an Integrative Secretion-Based Strategy.Microbial biotechnology · 2026Article
- Systematic perturbation of cultures of K. phaffii by carbon co-feeding show gene signatures associated with production of recombinant proteins.Microbial cell factories · 2026Article
- Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs.Frontiers in pediatrics · 2026Article
- Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25.Frontiers in pediatrics · 2026Article
- Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast.Veterinary sciences · 2025Article
- Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffii.Biotechnology and bioengineering · 2025Article
- Fine-tuning the N-glycosylation of recombinant human erythropoietin using Chlamydomonas reinhardtii mutants.Plant biotechnology journal · 2024Article
- CRISPR-Cas9 knockout screen informs efficient reduction of the Komagataella phaffii secretome.Microbial cell factories · 2024Article
- Promising non-model microbial cell factories obtained by genome reduction.Frontiers in bioengineering and biotechnology · 2024Review
- Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery.Bioconjugate chemistry · 2022Review
- Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2.ACS chemical biology · 2022Article
- Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.Frontiers in immunology · 2022Article
- Effect of cell retention techniques in Komagataella phaffii lab-scale continuous processes.Biotechnology progressArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33782611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.